BIOMAT Database Logo BIOMAT Database Logo

Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC + Tegafur regimen with or without levamisole. Report I. 1984

M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa

The usefulness of LMS in postoperative immunochemotherapy of gastric cancer was investigated. In compliance with the protocol, MMC was given at a dose of 20 mg on the day of gastrectomy, and an additional 10 mg on the next day IV. The patients receiving 600 mg Tegafur daily were then divided into two groups according to whether LMS was also given or not. LMS was administered for 3 days before the operation in a daily dose of 150 mg and for 1 year or more after operation according to a schedule of 3 days' administration followed by an 11-day interval. The 2-year follow-up demonstrated that in stage III patients, the LMS (+) regimen was superior to the LMS (-) regimen, since the former prolonged the relapse-free interval significantly. The survival rate for stage III disease was also significantly higher in the LMS (+) than in the LMS (-) group. There was no significant difference in the incidence of subjective or objective side-effects between two groups. The incidence of agranulocytosis was comparable in the two groups.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma.
January 1986, Cancer immunology, immunotherapy : CII,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
[Postoperative immunochemotherapy of gastric cancer using levamisole].
February 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
July 2003, International journal of oncology,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
August 2021, The British journal of radiology,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
Immunochemotherapy of gastric cancer with levamisole.
September 1980, Acta medica Okayama,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study.
January 1991, European journal of cancer (Oxford, England : 1990),
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
[A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer].
September 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
[Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer].
February 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
March 2004, British journal of cancer,
M Niimoto, and T Hattori, and I Ito, and R Tamada, and K Inokuchi, and K Orita, and H Furue, and N Ogawa, and T Toda, and M Furusawa
Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer--a randomized controlled trial.
July 1984, The Japanese journal of surgery,
Copied contents to your clipboard!